Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bradford Pontz

Internal Medicine Fairfax, VA Medical Doctor

NPI 1225097298 CMS profile 9826

8316 Arlington Blvd, Suite 310, Fairfax, VA 22031

Open in the dashboard

General payments

$6,117

290 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bradford Pontz of Fairfax, VA is reported in the CMS Open Payments database as having received $6,117 across 290 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $791 38
2024 General $915 39
2023 General $953 45
2022 General $1,024 54
2021 General $1,034 52
2020 General $796 37
2019 General $603 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bradford Pontz
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Bradford Pontz were reported at $791. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Bradford Pontz Internal Medicine median Middle half National median
2019 $603 $159 $48–$570 $163
2020 $796 $119 $33–$402 $114
2021 $1,034 $135 $37–$521 $132
2022 $1,024 $141 $42–$496 $149
2023 $953 $149 $45–$519 $160
2024 $915 $154 $47–$537 $164
2025 $791 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $825 46 payments
  2. AbbVie, Inc. $789 42 payments
  3. Pfizer Inc. $680 32 payments
  4. GlaxoSmithKline, LLC. $556 22 payments
  5. Amgen Inc. $482 19 payments
  6. Lilly USA, LLC $403 19 payments
  7. AstraZeneca Pharmaceuticals LP $225 13 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $155 7 payments
  9. Amarin Pharma Inc. $144 2 payments
  10. Mylan Specialty L.P. $142 6 payments
  11. Other $1,717 82 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,047 285 payments
  2. Education $69 5 payments
Products named General payments · program years 2019–2025
  1. Ozempic $691 38 payments
  2. RYBELSUS $652 36 payments
  3. UBRELVY $339 17 payments
  4. Prolia $331 10 payments
  5. SYNTHROID $317 17 payments
  6. SHINGRIX $241 11 payments
  7. AREXVY $236 10 payments
  8. EVENITY $228 10 payments
  9. ZEPBOUND $218 9 payments
  10. MOUNJARO $216 10 payments
  11. Other $4,918 238 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 82 drugs

Part D claims

2,488

Median for Internal Medicine: 777

Drug cost

$251,729

Median for Internal Medicine: $73,373

Branded share of claims

25.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 53 $49,000
Farxiga Dapagliflozin Propanediol Brand 44 $34,973
Jardiance Empagliflozin Brand 23 $28,097
Ozempic Semaglutide Brand 20 $25,382
Januvia Sitagliptin Phosphate Brand 19 $21,641
Tradjenta Linagliptin Brand 15 $14,743
Fiasp Flextouch Insulin Aspart (Niacinamide) Brand 14 $12,607
Xarelto Rivaroxaban Brand 12 $9,013
Synthroid Levothyroxine Sodium Brand 75 $7,537
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 23 $7,054

The 10 drugs with the highest cost, of 82 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$219,567

Of which drugs: $94,800

Medicare patients

304

Average age 79

Services billed

4,844

143 women, 161 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 43%
Ischemic heart disease 22%
Osteoporosis 21%
Atrial fibrillation 19%
Diabetes 18%
Cancer 16%
Depression 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 22 2,640 $53,923
Sarscv2 vac 30mcg trs-suc im 91320 Office 154 207 $28,810
Vaccine for influenza for injection into muscle 90662 Office 127 130 $10,487

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SHINGRIX
  • GlaxoSmithKline, LLC. $124
$124 — —
MOUNJARO
  • Lilly USA, LLC $79
$79 — —
ZEPBOUND
  • Lilly USA, LLC $74
$74 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $30
  • Lilly USA, LLC $27
$57 23 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $51
$51 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

290 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record